PYC
GOODPhysiomics Awarded New Contract
The healthcare company has secured a new contract worth £47,600 to provide modelling and simulation services for the development of a novel antibody therapy.
Physiomics
0.4660GBX
5.91%
Market Cap
1.41M
Volume
12.11M
194% of avg
P/E Ratio
-0.01
EPS (TTM)
-0.34
Beta
1.59
Day Range
0.4330p - 0.4833p
52 Week Range
0.3800p0.4660p1.6690p
0.4660p
Upcoming Events
PYC
NEUTRALPhysiomics Publishes Peer-Reviewed Article on Immunotherapy Drug Development
The biotechnology company has published a peer-reviewed article on its mathematical modelling approach to supporting the development of a novel immunotherapy drug.
PYC
GOODPhysiomics Awarded New Contract by Numab Therapeutics
The healthcare company has been awarded a new contract by Numab Therapeutics to apply modelling and simulation techniques to support pre-clinical development of a cancer treatment.
PYC
GOODPhysiomics Wins New Contract with UK Biotech Firm
The healthcare technology company has secured a new contract with a UK biotech firm to develop a pharmacokinetic and pharmacodynamic model for an upcoming clinical trial.
PYC
NEUTRALPhysiomics Provides Investor Presentation Update
The healthcare company has updated its website with a recent investor presentation, providing no additional financial or operational details.
PYC
BADPhysiomics Reports Revenue Decline and Increased Losses in Half-Year Results
The biotech consulting firm reported declining revenues and widening losses in its half-year results, despite new contract wins and progress in software development. Management remains optimistic about full-year prospects.
PYC
NEUTRALPhysiomics Plc Announces Upcoming Interim Results and Investor Presentation
The healthcare company will be posting interim results and hosting an investor presentation in the coming weeks, providing shareholders an opportunity to engage with management.
PYC
NEUTRALPhysiomics Plc Announces Director Shareholding Change
The healthcare company has disclosed a change in director shareholding, with no further details provided.
PYC
NEUTRALPhysiomics Plc Completes £500,000 Fundraise
The biotechnology company has completed a £500,000 fundraise, with the proceeds to be used for business development and growth. The raise was at a modest discount to the previous share price.
PYC
BADPhysiomics Plc Announces Discounted Placing and WRAP Retail Offer
The biotechnology company is raising capital through a discounted Placing and WRAP Retail Offer, but the details raise concerns about its financial position and growth prospects.